How Long Does Cagrilintide Stay in Your System? What the Research Reports

The short answer, in plain terms

Cagrilintide was developed as a long-acting amylin analogue intended for once-weekly subcutaneous administration, and the medicinal-chemistry paper describing its development attributed that duration of action to a lipidated design that extends circulation time (PMID 34288673). A once-weekly dosing interval is itself a pharmacokinetic statement: a compound given every seven days has to persist in measurable concentrations across that whole interval, which places cagrilintide in the days-to-weeks category rather than the minutes-to-hours category occupied by native amylin and many unmodified peptides.

That is the honest limit of what can be said without inventing numbers. Where compound-specific pharmacokinetic (PK) data exist for cagrilintide, this page says so and links the source. Where a point is general peptide pharmacology rather than a cagrilintide measurement, this page labels it as such. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, investigational or approved.

What cagrilintide is, and its regulatory position

Amylin is a pancreatic hormone co-secreted with insulin, and reviews of the field describe amylin receptors as a therapeutic target in obesity with several peptide-based agonists in development (PMID 41344603). A structural pharmacology study reported that cagrilintide activates both amylin and calcitonin receptors, and the researchers described the mechanistic basis for that dual activation (PMID 40847076). A five-year perspective on amylin pharmacology placed these agents within the broader treatment landscape for obesity and type 2 diabetes (PMID 41549439).

Cagrilintide has been studied as a prescription-track investigational medicine, including in combination with semaglutide, rather than as a consumer product. A randomised, controlled phase 1b trial evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of cagrilintide given with semaglutide 2.4 mg for weight management (PMID 33894838). Any question about whether a medicine of this class is appropriate for a particular person, at any dose or schedule, belongs with a prescribing clinician — this page does not address it.

Why a weekly interval implies a long half-life

The chemistry behind the duration

Small peptides are cleared quickly because they are degraded by peptidases and filtered by the kidney. The strategy used to defeat that is acylation: attaching a fatty-acid side chain so the peptide binds reversibly to circulating albumin, which both shields it from degradation and slows renal filtration. The development paper for cagrilintide reported that this long-acting design was the goal of the programme and produced an analogue suitable for once-weekly administration (PMID 34288673).

This is the same general principle that underlies other weekly injectables, and it is why the practical answer to "how long does it stay in your system" is governed by albumin binding rather than by the peptide backbone alone. The broader mechanism is covered in how long peptides stay in your system.

The arithmetic of elimination (general pharmacology, not a cagrilintide measurement)

Most drugs are eliminated by first-order kinetics, meaning a constant fraction disappears per unit time. The table below is textbook arithmetic applied to any half-life — it is not a reported cagrilintide figure and no study on this page measured it:

Pharmacology convention treats roughly four to five half-lives as functional washout. Applied to a compound engineered for weekly dosing, that arithmetic points to a washout window measured in weeks rather than days — but the specific number of weeks for cagrilintide is a question for the PK data in the trial record and the prescribing information, not for extrapolation on an educational page.

Accumulation and steady state

A second consequence of long half-lives is accumulation. When dosing intervals are shorter than four to five half-lives, each dose lands on residual drug from previous doses and average concentrations climb until input matches elimination — the steady state. This is standard pharmacokinetics, and it is the reason multiple-dose trials exist at all: single-dose data cannot predict steady-state exposure. The phase 1b trial examined multiple doses of cagrilintide co-administered with semaglutide 2.4 mg precisely so that pharmacokinetics and pharmacodynamics could be characterised under repeated dosing (PMID 33894838).

Practically, this means two different clocks run at the same time: the time for concentrations to build to steady state after dosing begins, and the time for concentrations to fall away after dosing stops. For long-acting agents these two periods are of similar length, both driven by the same half-life.

What changes how fast it clears

Kidney and liver function: the cagrilintide-specific finding

Renal and hepatic impairment are the first variables investigators test for any new agent, because both organs can govern elimination. A clinical pharmacokinetics study examined subcutaneous cagrilintide in this context and reported that renal or hepatic impairment did not affect its pharmacokinetics, safety or tolerability (PMID 42228334). That is an unusually clean result and is consistent with an albumin-bound peptide whose disposition is dominated by proteolytic catabolism distributed across tissues rather than by a single excretory organ.

It is worth stating what that finding does and does not mean. The study addressed pharmacokinetic exposure; it is not a statement about whether any individual with organ impairment should receive the medicine, which remains a clinical judgement made by a prescriber with the full label and trial record in front of them.

Factors described in general peptide pharmacology

Beyond organ function, the variables that modify exposure to subcutaneously injected, albumin-bound peptides are well described in general pharmacology rather than in cagrilintide-specific publications. They include:

• Injection site and depot behaviour — subcutaneous absorption rate varies with tissue perfusion and site, which shapes peak timing more than total exposure.
• Body size and composition — volume of distribution scales with body size, so exposure per milligram differs between individuals.
• Serum albumin concentration — binding capacity influences the free fraction of acylated peptides.
• Anti-drug antibodies — immunogenicity can alter clearance of therapeutic peptides in a minority of recipients.
• Dose history — where a person sits relative to steady state changes measured concentrations independently of any biological difference.

None of those bullet points is a cagrilintide measurement; they are the standard list of modifiers for this drug class, offered so readers can see why two people on identical schedules do not have identical concentrations.

Does cagrilintide show up on a drug test?

Stated plainly: routine drug testing does not look for cagrilintide. Standard workplace and clinical urine panels are designed around drugs of abuse — amphetamines, cannabinoids, cocaine metabolites, opiates, phencyclidine, and in extended panels benzodiazepines, barbiturates and a handful of others. Peptide hormones and peptide analogues are not part of those panels, are not detected by the immunoassays those panels use, and would not produce a positive or a false positive on them.

Measuring cagrilintide requires a purpose-built bioanalytical assay — typically liquid chromatography coupled to mass spectrometry or a validated immunoassay developed for the specific molecule. Those assays exist inside drug development programmes, which is how pharmacokinetics are characterised in trials such as the phase 1b study of cagrilintide with semaglutide 2.4 mg (PMID 33894838), and in the clinical pharmacokinetics work on renal and hepatic impairment (PMID 42228334). They are not commercially available as consumer or employer tests.

Routine blood chemistry panels likewise do not report peptide-drug concentrations. For readers subject to anti-doping regulation, whether any given hormone analogue falls within a prohibited class is determined by the current published Prohibited List of the relevant anti-doping authority and by the athlete's governing body, not by general pharmacology — those documents are the authoritative source and are revised annually.

Tolerability and Adverse Events: What Studies Report

The phase 1b trial of multiple doses of cagrilintide with semaglutide 2.4 mg reported that adverse events were predominantly gastrointestinal and mostly mild to moderate in severity, which is the pattern researchers have described for this therapeutic area generally (PMID 33894838). A pharmacological review examining amylin-based pharmacotherapy framed the central question for the class as the search for better-tolerated weight-loss drugs beyond GLP-1 receptor agonists (PMID 42586227).

Tolerability intersects with pharmacokinetics in one specific way worth noting: with a long-acting agent, adverse effects do not resolve the moment dosing stops, because concentrations decline over the same multi-day timescale that gives the compound its weekly interval. That is a general pharmacological consequence of a long half-life rather than a specific reported finding, and management of any adverse effect is a clinical matter.

Why class data do not transfer

Amylin receptor agonists differ substantially from one another in structure and in half-life. A 2025 report on eloralintide described a separate amylin receptor agonist developed for obesity, taken from discovery through clinical proof of concept (PMID 41109426), and structural work showed that cagrilintide's receptor engagement spans both amylin and calcitonin receptors (PMID 40847076). Pharmacokinetic figures from one molecule in a class should not be read across to another; half-life is a property of the individual molecule's chemistry, not of the receptor it targets.

What the published record does not settle

• Exact elimination half-life values and clearance parameters for cagrilintide in defined populations are matters for the full trial record and regulatory documentation, not for extrapolation.
• How long any pharmacodynamic effect persists after concentrations fall is a separate question from how long the molecule is detectable, and the two timelines do not have to match.
• Comparative reviews of amylin pharmacology continue to describe the field as evolving rather than settled (PMID 41549439).

Related reading

• Cagrilintide: what the research describes
• How long do peptides stay in your system?

References

• Development of Cagrilintide, a Long-Acting Amylin Analogue (Journal of Medicinal Chemistry, 2021)
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial (Lancet, 2021)
• Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide (Clinical Pharmacokinetics, 2026)
• Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors (Acta Pharmacologica Sinica, 2026)
• Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies (Vascular Pharmacology, 2026)
• Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity (Journal of Obesity & Metabolic Syndrome, 2026)
• Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs (Pharmacological Research, 2026)
• Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept (Molecular Metabolism, 2025)